Statins and Testosterone in Men Over 40: How Much They Actually Lower It, What They Do to Muscle and Training, and How to Decide Whether You Need One

Statins lower testosterone by roughly 19 ng/dL in randomized trials, an amount most men would never notice and smaller than the effect of a single inch of waist. The muscle story is more complicated: most statin muscle pain disappears on placebo, but one trial showed simvastatin erasing nearly all of the fitness gain from 12 weeks of training. This guide separates the effects that matter for a man over 40 from the ones that do not, and lays out how to decide whether a statin belongs in the plan.

Statins and testosterone in men over 40 is a question that comes up in almost every consultation where a man has just been handed a prescription for atorvastatin and is already worried about his hormones. Cholesterol is the raw material every steroid hormone is built from, so it seems obvious that a drug which cuts cholesterol production should cut testosterone too. The randomized trials say it does, by an amount so small that it is hard to detect without pooling hundreds of men. The bigger questions for a man who lifts, runs or is on testosterone therapy are what statins do to muscle, to training adaptation, to blood sugar and to erections, and whether he needs the drug in the first place.

This guide walks through what the pooled trials found on testosterone, why the effect is smaller than the biochemistry predicts, what the SAMSON trial revealed about statin muscle pain, the one simvastatin study every man who trains should know about, the diabetes signal, how a coronary calcium score changes the decision, whether statins and testosterone therapy can be combined, and a 6 month plan for starting a statin without giving up muscle or hormones.

Statins lower testosterone in men by a small, measurable amount, on average about 0.66 nmol/L or 19 ng/dL, according to the only meta-analysis of randomized trials on the question. Schooling and colleagues at the University of Hong Kong pooled five placebo-controlled trials covering 501 men, mostly middle-aged with high cholesterol on ordinary statin doses, and found the reduction was consistent in direction and statistically significant but too small for any individual trial to have picked up. For a man starting at 500 ng/dL that is a drop to roughly 480, well inside the day-to-day variation of the test itself.

The observational data point the same way with slightly larger numbers. Corona and colleagues in Florence examined 3,484 men who had come to a clinic for erectile dysfunction and found that the men on statins had lower total and calculated free testosterone than men not on statins, after adjusting for age, body mass index and cardiovascular risk. LH was not suppressed, which suggests the effect happens at the testicle rather than at the pituitary: the Leydig cells are making slightly less hormone, not receiving less instruction to make it. Clinic populations of men with erectile dysfunction are not representative, and men prescribed statins are on average heavier and more insulin resistant than men who are not, so the observational gap almost certainly overstates what the drug itself does.

The chart is the point. A statin costs a man roughly what one extra inch of waist costs him, and a fraction of what a week of short sleep, untreated sleep apnea or a daily painkiller costs him. Men who blame a statin for a testosterone that has fallen from 550 to 350 ng/dL are almost always looking at the wrong culprit, and the waist-to-height ratio, the sleep and the alcohol usually explain the gap several times over.

The testosterone effect is small because Leydig cells do not depend on circulating LDL cholesterol for their supply; they synthesise cholesterol themselves and, when blood levels fall, they respond by making more of it and by putting more LDL receptors on their surface to capture what remains. Statins block HMG-CoA reductase, the rate-limiting enzyme in cholesterol synthesis, mostly in the liver where the drug concentrates. The testicle sees a far lower drug concentration, and even a 50 percent fall in serum LDL leaves more than enough cholesterol arriving to run steroid production, which uses a tiny fraction of the body's cholesterol turnover.

Whether the statin is lipophilic or hydrophilic probably matters at the margin. Simvastatin, atorvastatin and lovastatin dissolve in fat and cross cell membranes freely, so they reach muscle and testicular tissue more readily. Rosuvastatin and pravastatin are water soluble and depend on a transporter that is concentrated in the liver, so relatively less drug reaches other tissues. The trials in the Schooling analysis were dominated by simvastatin and atorvastatin, and the muscle literature consistently shows more myopathy with lipophilic statins at high dose, which is why the FDA restricted simvastatin 80 mg in 2011. For a man over 40 who is worried about hormones and muscle, rosuvastatin at a moderate dose is the usual first choice for exactly this reason.

Statins improve erectile function on average rather than harming it: the Kostis 2014 meta-analysis of 11 randomized trials found the IIEF erectile function score rose by 3.4 points on statins compared with control, roughly a third of the improvement seen with a PDE5 inhibitor such as sildenafil. The mechanism is the same reason statins reduce heart attacks. Erections depend on the lining of the penile arteries releasing nitric oxide, and statins improve that endothelial response within weeks, well before any plaque regresses. Men with erectile dysfunction and high cholesterol who start a statin often find the tablet helps more than it hurts.

The apparent contradiction with the Corona data resolves once the sizes are compared. A 19 ng/dL fall in testosterone is nowhere near enough to affect erections, which are only reliably impaired by testosterone well below 300 ng/dL, while the endothelial improvement acts directly on the tissue that produces the erection. Men who notice worse erections after starting a statin should look first at the nocebo effect, at the blood pressure tablet that was often started the same week, and at the diagnosis that prompted the prescription, since arterial disease severe enough to warrant a statin at 45 is itself a leading cause of erectile dysfunction.

Statins cause genuine muscle pain in a small minority of men, but most of the muscle pain attributed to statins is nocebo, and the best evidence for that is the 2020 SAMSON trial. Sixty patients who had abandoned statins because of intolerable muscle symptoms were given twelve one-month bottles in random order: four of atorvastatin 20 mg, four of identical placebo and four empty. Symptom scores were near zero in the empty months and nearly identical in the atorvastatin and placebo months. Ninety percent of the symptom burden felt on the real statin was also felt on the placebo. Half the participants restarted a statin after seeing their own data. The Cholesterol Treatment Trialists' 2022 analysis of 19 double-blind trials and 123,940 participants reached the same conclusion from the other direction: statins raised reports of muscle pain or weakness by 7 percent in the first year and not at all afterwards, meaning only about one in fifteen reports of muscle symptoms on a statin is actually caused by the drug.

The exception that matters for men who train is adaptation, not pain. Mikus and colleagues randomized 37 previously sedentary adults with metabolic syndrome risk factors to 12 weeks of supervised aerobic training either alone or with simvastatin 40 mg. The training-only group improved VO2 max by 10 percent and raised citrate synthase, a marker of mitochondrial content in muscle, by 13 percent. The group on simvastatin improved VO2 max by 1.5 percent and their citrate synthase fell by 4.5 percent. The statin did not make them sore; it stopped the muscle from adapting. The study was small, used a lipophilic statin at a fairly high dose, and has not been cleanly replicated, but it is the reason many sports physicians steer men who train hard toward hydrophilic statins at the lowest effective dose.

The reassuring counterweight is a 2021 JACC trial by Allard and colleagues in which symptomatic and asymptomatic statin users completed 12 weeks of moderate intensity training. Muscle performance improved in both groups and symptoms did not worsen, so a man on a statin can still get fitter; he may simply get less benefit per session from a high dose of a lipophilic statin than he would drug free. CoQ10 is the supplement most often suggested here because statins lower blood CoQ10 by roughly 40 percent. The Qu 2018 meta-analysis of 12 small trials found CoQ10 at 100 to 600 mg a day reduced muscle symptom scores, though the trials were weak and the largest ones were negative. At 100 to 200 mg a day it is cheap and harmless, which is the strongest argument for it.

Statins raise the rate of new type 2 diabetes by about 9 percent in relative terms, which works out to roughly one extra diagnosis for every 255 people treated for four years, and the excess falls almost entirely on people who were already prediabetic. The Sattar 2010 meta-analysis in the Lancet of 13 trials and 91,140 participants established the number, and the Preiss 2011 analysis in JAMA found intensive doses added a further 12 percent over moderate doses. The mechanism is a small worsening of insulin sensitivity and a small reduction in insulin secretion. HbA1c typically rises by 0.1 to 0.2 percent, which only crosses a diagnostic line in a man who was standing on it.

For a man over 40 with a waist-to-height ratio above 0.5, a fasting insulin above 10 and an HbA1c of 5.8, this matters more than the testosterone effect. The same trials that found the diabetes signal found that the cardiovascular benefit in those same people outweighed it by a wide margin, which is why guidelines do not withhold statins from prediabetic men. The practical response is to treat the statin as a reason to fix the insulin resistance rather than a reason to refuse the drug: the waist, the resistance training and, where indicated, a GLP-1 drug move HbA1c by ten times what the statin moves it in the other direction.

A man over 40 decides whether he needs a statin by combining three numbers: his ApoB or LDL cholesterol, his lipoprotein(a), and his coronary artery calcium score, rather than by acting on a single cholesterol reading. Each 1 mmol/L (39 mg/dL) reduction in LDL cuts the risk of a major vascular event by about 22 percent per year of treatment in the Cholesterol Treatment Trialists' pooled data, and the benefit is proportional: a man with a lot of plaque and a high LDL gains a great deal, and a man with no plaque and a moderately high LDL gains very little over the next decade. The calcium score is what separates the two.

In the MESA cohort, adults aged 45 to 84 with a coronary calcium score of zero had roughly a 1.5 percent ten-year rate of coronary events even when LDL was above 160 mg/dL, low enough that the 2018 American guidelines allow a statin to be deferred in intermediate-risk adults with a zero score and no other high-risk feature. A score above 100 puts a man in the range where a statin is clearly justified regardless of how he feels about his testosterone, and a score above 300 places his risk on a par with someone who has already had a heart attack. A high lipoprotein(a), which statins do not lower, pushes the decision toward treating everything else more aggressively.

A statin and testosterone therapy can be taken together without any drug interaction, and for many men over 40 the combination is the right one, because the same visceral fat that drove the LDL up also drove the testosterone down. Testosterone therapy itself has a small effect on lipids: HDL falls by about 2 to 5 mg/dL, LDL and total cholesterol fall slightly or not at all, and the 2023 TRAVERSE trial in 5,246 men with low testosterone and existing cardiovascular risk found no increase in major cardiac events over three years. Injectable and transdermal testosterone at physiological doses do not change the statin decision; supraphysiological doses and oral 17-alpha-alkylated androgens, which crash HDL, are a different matter and are not used in medical therapy.

The reverse question, whether testosterone therapy blunts the statin's testosterone effect, is trivially yes, since the dose is set by blood level and a 19 ng/dL shift disappears in the adjustment. The more useful observation is that GLP-1 drugs, which many men over 40 are now offered alongside a statin, lower LDL by about 5 to 10 percent and triglycerides by 15 to 25 percent through weight loss, and in a man whose calcium score is low that reduction, plus the waist coming down, sometimes removes the need for the statin altogether. Retesting lipids after six months of weight loss before committing to a statin is a reasonable sequence for a man with a zero or low calcium score.

Statins lower testosterone by about 19 ng/dL, roughly the cost of one extra inch of waist and far below what short sleep, sleep apnea or a nightly drink take away. They improve erections on average, they cause real muscle pain in about one man in fifteen who reports it, and a high dose of a lipophilic statin can blunt the fitness gains from training, which is why a man who lifts or runs should be on rosuvastatin at the lowest dose that holds his ApoB at target, with ezetimibe added before the dose is doubled. None of that decides whether a given man needs the drug. The calcium score, the ApoB and the lipoprotein(a) decide that, and a man over 40 who gets those three numbers before he argues about his testosterone will usually find the argument settles itself.

Continue Reading

Related Articles

Hormones

Cholesterol, ApoB, and TRT: What Testosterone Therapy Actually Does to Your Lipid Panel

12 min read

Read Article →

Longevity

Coronary Calcium Score for Men Over 40: The $100 Scan That Reclassifies Your Heart Risk

13 min read

Read Article →

Hormones

Insulin Resistance and Testosterone: The Fasting Number Men Forget to Order

12 min read

Read Article →